{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    42,
    43,
    45,
    46,
    50,
    62,
    67,
    198,
    199,
    73,
    75,
    78,
    79
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "Day 1 dosing",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "baseline visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 20,
        "sourceText": "Screening visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "Informed consent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "surgery",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "surgery",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_10",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "PK sampling at "
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "sourceText": "Screening Period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "1 day after"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "14 days post"
      },
      {
        "id": "rep_llm_1",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P0D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "End of study",
        "sourceText": "Time period and frequency for collecting AE and SAE information"
      },
      {
        "id": "rep_llm_2",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P6D",
        "interval": "P1D",
        "minObservations": 6,
        "exitCondition": "Completion of 6 exposure days",
        "sourceText": "Participants should have at least 6 EDs to BIVV001 to be eligible for major surgery."
      },
      {
        "id": "rep_llm_3",
        "type": "Continuous",
        "startOffset": "-P7D",
        "endOffset": "P0D",
        "interval": "P7D",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "the PROMIS-SF Physical Function - SF 6b instrument does not use a 7-day recall period"
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "P0D",
        "interval": "P28D",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "negative inhibitor test within 4 weeks prior to surgery"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "WASHOUT",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "washout period"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "End of Study",
          "Screening",
          "Day 1",
          "Baseline"
        ],
        "sourceText": "[{'condition': 'If subject undergoes major surgery', 'path': ['SURGERY_SUBGROUP', '6_EXPOSURE_DAYS_MINIMUM', 'NEGATIVE_INHIBITOR_TEST']}, {'condition': 'Use of FVIII products other than BIVV001 (non-emergency)', 'path': ['DEFINITIVE_DISCONTINUATION']}, {'condition': 'Life-threatening emergency requiring other FVIII product', 'path': ['SPONSOR_REVIEW', 'CONTINUATION_OR_DISCONTINUATION']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "EPISODE signals: 2; SINGLE signals: 8"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "SINGLE signals: 6"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 11; RECURRING signals: 3"
      },
      {
        "activityId": "Laboratory Assessments",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Dosing",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; SINGLE signals: 8"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Haem-A-QoL (≥17 years old) Physical Health score",
        "executionType": "Single",
        "rationale": "Secondary efficacy endpoint measures like PROs are typically scheduled repeats at specific study visits as per the Schedule of Activities."
      },
      {
        "activityId": "PROMIS Pain Intensity 3a",
        "executionType": "Single",
        "rationale": "Patient Reported Outcome measures are scheduled for collection at multiple study visits to assess efficacy over time."
      },
      {
        "activityId": "Hemophilia Joint Health Score (HJHS)",
        "executionType": "Single",
        "rationale": "Total score measures for joint health are assessed at scheduled intervals throughout the study duration."
      },
      {
        "activityId": "Treatment Satisfaction Questionnaire for Medication (TSQM-9)",
        "executionType": "Single",
        "rationale": "Standardized questionnaires in Phase 3 trials are administered at recurring scheduled visits to track patient satisfaction."
      },
      {
        "activityId": "Exit Interview",
        "executionType": "Single",
        "rationale": "The exit interview is a one-time assessment conducted at the end of the participant's involvement in the study."
      },
      {
        "activityId": "ABR (Annualized Bleed Rate) Monitoring",
        "executionType": "Single",
        "rationale": "ABR requires continuous monitoring and recording of bleeding events over a 6-month period to calculate the rate."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutDuration": "P96D",
      "washoutRequired": true,
      "sourceText": "washout period"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening Period is up to 8 weeks before Baseline. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results.",
        "footnoteId": "fn_1",
        "structuredCondition": "timing.before(Baseline, P8W) && timing.after(InhibitorTest, PT48H)",
        "appliesToActivityIds": [
          "Screening",
          "Inhibitor Test"
        ],
        "timingConstraint": "PT48H",
        "sourceText": "a. Screening may be accomplished over the course of more than 1 study visit if needed. The Screening"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period before the Baseline Visit for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor.",
        "footnoteId": "fn_2",
        "structuredCondition": "if(product == 'conventional') timing.after(last_dose, PT96H) else if(product == 'EHL') timing.after(last_dose, PT120H)",
        "appliesToActivityIds": [
          "BIVV001 Day 1 Dose"
        ],
        "timingConstraint": "PT96H",
        "sourceText": "b. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participa"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_after",
        "text": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic dose of BIVV001.",
        "footnoteId": "fn_3",
        "structuredCondition": "timing.after(previous_dose, P7D) +/- P1D",
        "appliesToActivityIds": [
          "Study Visits"
        ],
        "sourceText": "c. Participants should schedule their study visits to be 7 ±1 day after the previous prophylactic do"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_after",
        "text": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in the Sequential PK arm should schedule their Week 26 study visit to be 7 (+2) days after the previous prophylactic dose of BIVV001.",
        "footnoteId": "fn_4",
        "structuredCondition": "if(arm == 'Sequential PK') timing.after(previous_dose, P7D) + P2D",
        "appliesToActivityIds": [
          "Week 26 Visit"
        ],
        "sourceText": "d. At this visit, participants in Arm B (on-demand treatment) switch to prophylaxis. Participants in"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "eligibility_conditional",
        "text": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or at the discretion of the Investigator. If a participant has an unscheduled visit, the Investigator will record data as appropriate based on the purpose of the visit.",
        "footnoteId": "fn_5",
        "sourceText": "e. Unscheduled visits may be necessary during the study to repeat any blood sampling if required, or"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "timing_after",
        "text": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant enrolls in the open-label extension study. For France specific pregnancy testing at the safety follow-up visit refer to Section 10.11.1.",
        "footnoteId": "fn_6",
        "structuredCondition": "timing.after(last_dose, P14D) + P7D",
        "appliesToActivityIds": [
          "Safety Follow-up Call",
          "Safety Follow-up Visit"
        ],
        "sourceText": "f. This call or visit will occur 14 (+7) days after the last dose of BIVV001, unless the participant"
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior to any study-related procedures, including washout of current FVIII therapy specifically for entry into the study, or the country's local regulations. Participant assent must also be obtained where applicable (according to the study site's geographic region).",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.before(any_procedure, PT0S)",
        "appliesToActivityIds": [
          "Informed Consent"
        ],
        "sourceText": "g. Informed consent from the participant or the participant's legal guardian MUST be obtained prior "
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted by local regulations. Race and ethnicity will be collected for reasons described in Section 10.1.4.",
        "footnoteId": "fn_8",
        "sourceText": "h. Demographics include sex, race, ethnicity, and date of birth (year of birth only), as permitted b"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not previously documented. For Repeat Screening Visit, update with any changes since original Screening Visit.",
        "footnoteId": "fn_9",
        "sourceText": "i. Includes hemophilia history assessment of disease severity, blood type, and Rh factor if not prev"
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committees) will be governed by a separate informed consent. HLA genotype will not be needed if previously documented.",
        "footnoteId": "fn_10",
        "sourceText": "j. Collection of samples for genotype analysis (as permitted by local regulations and ethics committ"
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test results. Washout prior to BIVV001 Day 1 dose administration is at least 96 hours (4 days) if the participant is receiving a conventional FVIII product and at least 120 hours (5 days) if current treatment is with an EHL FVIII product. The washout period prior to BIVV001 Day 1 dose administration for subjects in abbreviated PK sampling may be modified at the discretion of the Investigator based on individual PK data and clinical phenotype in consultation with medical monitor. Washout prior to all other scheduled inhibitor tests must be at least 7±1 days. Inhibitor and ADA samples will be collected prior to BIVV001 dosing. Separate samples for anti-rFVIIIFc-VWF-XTEN antibody (ADA) testing will be collected at the same timepoint when any samples are collected for inhibitor testing (including samples for suspected inhibitor and confirmatory inhibitor tests). All inhibitor assays, including the assay for the Screening Visit and any confirmatory assays, will be performed by the central laboratory using the Nijmegen-modified Bethesda assay. If a Nijmegen-modified Bethesda assay result returns as ≥0.6 BU/mL, a separate sample must be collected and tested for confirmation of inhibitor development within 2 to 4 weeks of the original sample. Testing for potential ADA formation will be performed at a central laboratory using a validated rFVIIIFc-VWF-XTEN-specific ADA assay. Confirmed positive samples will be further characterized for antibodies specific to FVIII, Fc, D'D3, or XTEN.",
        "footnoteId": "fn_11",
        "structuredCondition": "timing.after(original_sample, P2W) && timing.before(original_sample, P4W)",
        "appliesToActivityIds": [
          "Inhibitor Confirmation Test"
        ],
        "timingConstraint": "PT48H",
        "sourceText": "k. Washout prior to the Screening inhibitor test is at least 48 hours to obtain interpretable test r"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participants in Arm B will have BIVV001 doses at visits Day 1, Weeks 26, 39, and 52. During the Scheduled study visits, BIVV001 will be delivered via a slow push IV injection of 8 ±2 minutes, at a rate of administration determined by the participant's comfort level. For all BIVV001 injections performed at home BIVV001 will be delivered via a slow push IV injection at a rate of administration determined by the participant's comfort level according to the vial and injection rate recommendations (Table 7). Injection start and stop time will be recorded in the eCRF. Other doses may be self/caregiver administered at home (or in clinic) (Table 3)",
        "footnoteId": "fn_12",
        "sourceText": "l. Participants in Arm A will have BIVV001 doses given at each applicable scheduled visit. Participa"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "timing_after",
        "text": "m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (°C). Vital signs should be taken after the participant has been resting supine for 5 minutes. Vital signs will be measured pre-injection and 30 (±15 minutes) from the start of injection at clinic visits. Vital signs should also be taken at any unscheduled visit.",
        "footnoteId": "fn_13",
        "structuredCondition": "timing.after(rest, PT5M) && timing.before(injection, PT0S) && timing.after(injection_start, PT30M) +/- PT15M",
        "appliesToActivityIds": [
          "Vital Signs"
        ],
        "timingConstraint": "PT5M",
        "sourceText": "m. Vital signs include blood pressure, pulse rate, respiratory rate, and temperature (°C). Vital sig"
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "n. Applicable to female participants only. A serum pregnancy test should be performed at screening. For all other time points, the choice of the pregnancy test (urine or serum) is at the discretion of the Investigator. If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from further participation if the serum pregnancy result is positive.",
        "footnoteId": "fn_14",
        "structuredCondition": "if(sex == 'female') procedure.perform(Pregnancy Test)",
        "appliesToActivityIds": [
          "Pregnancy Test"
        ],
        "sourceText": "n. Applicable to female participants only. A serum pregnancy test should be performed at screening. "
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o. For participants who have been historically negative, viral testing will be performed at a central laboratory. Human immunodeficiency virus (HIV) tests will include HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen. Hepatitis B virus (HBV) tests will include HBV surface antigen, anti-HBV surface antibody and anti-HBV core antibody. Hepatitis C virus (HCV) tests will include anti-HCV antibodies.",
        "footnoteId": "fn_15",
        "sourceText": "o. For participants who have been historically negative, viral testing will be performed at a centra"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "timing_before",
        "text": "p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be performed at the central laboratory if results are not available from within 26 weeks prior to screening.",
        "footnoteId": "fn_16",
        "sourceText": "p. For participants known to be HIV antibody positive, CD4 count and viral load tests must be perfor"
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_before",
        "text": "q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differential, platelet count, hemoglobin (Hgb), and hematocrit (Hct). Blood samples for hematology analysis will be collected prior to BIVV001 dosing.",
        "footnoteId": "fn_17",
        "structuredCondition": "timing.before(BIVV001_dosing, PT0S)",
        "appliesToActivityIds": [
          "Hematology"
        ],
        "sourceText": "q. Hematology parameters include red blood cell (RBC) count, white blood cell (WBC) count and differ"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "timing_before",
        "text": "r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma glutamyl transferase (GGT), bilirubin, blood urea nitrogen (BUN), creatinine, glucose, total protein, sodium, potassium, and chloride. Blood samples for clinical chemistry analysis will be collected prior to BIVV001 dosing.",
        "footnoteId": "fn_18",
        "structuredCondition": "timing.before(BIVV001_dosing, PT0S)",
        "appliesToActivityIds": [
          "Clinical Chemistry"
        ],
        "sourceText": "r. Clinical chemistry parameters include alanine aminotransferase (ALT), aspartate aminotransferase "
      },
      {
        "id": "fn_cond_19",
        "conditionType": "timing_before",
        "text": "s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] ristocetin cofactor activity and VWF antigen). Blood samples for analysis of Von Willebrand comprehensive panel will be collected prior to any BIVV001 dosing.",
        "footnoteId": "fn_19",
        "sourceText": "s. The Von Willebrand comprehensive panel (includes assessments of von Willebrand Factor [VWF] risto"
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_before",
        "text": "t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed consent form (ICF) through the Safety Follow-Up Call or Visit will be recorded on the case report form (CRF). Pain medication related to Hemophilia and administered within 2 weeks prior to the visit will be recorded on the CRF.",
        "footnoteId": "fn_20",
        "sourceText": "t. Adverse events (AEs) and serious adverse events (SAEs) occurring after signing of the informed co"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "timing_before",
        "text": "u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies and procedures from signing of ICF through the Safety Follow-Up Call or Visit will be recorded on the CRF.",
        "footnoteId": "fn_21",
        "sourceText": "u. Prior and concomitant medications from up to 30 days prior to Screening and concomitant therapies"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month for the site staff to check on each participant's status. During the monthly telephone call, the participant's parent/caregiver will also be reminded about the requirement for timely ePD data entry, and assessments of \"spontaneous\" and \"traumatic\" bleeding episodes will be noted.",
        "footnoteId": "fn_22",
        "sourceText": "v. In addition to scheduled clinic visits, telephone calls are planned approximately once a month fo"
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS). At baseline, the Investigator will assess the presence of any target joints according to ISTH criteria.",
        "footnoteId": "fn_23",
        "sourceText": "w. Investigator will examine each participant's joints per the Haemophilia Joint Health Score (HJHS)"
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "x. For bleeding episodes treated at the study sites, the Investigator will contact the participant approximately 72 hours from the time the BIVV001 injection was administered to treat the bleeding episode and record the participant's assessment of response to BIVV001 treatment on the eCRF using a 4-point bleeding response scale. For bleeding episodes that are treated at home, participants will record response to bleeding episodes in the ePD.",
        "footnoteId": "fn_24",
        "sourceText": "x. For bleeding episodes treated at the study sites, the Investigator will contact the participant a"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "timing_after",
        "text": "y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity and Damage Examination (JADE) protocol and/or Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) in a subpopulation of participants from Arm A at selected sites. The Ultrasound can be performed at the Baseline visit or up to 2 weeks after the Baseline Visit.",
        "footnoteId": "fn_25",
        "structuredCondition": "timing.at(Baseline) || timing.after(Baseline, P2W)",
        "appliesToActivityIds": [
          "Ultrasound Imaging"
        ],
        "sourceText": "y. Anatomical structural joint-health assessment via ultrasound imaging per Joint Tissue Activity an"
      },
      {
        "id": "fn_cond_26",
        "conditionType": "timing_before",
        "text": "z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laboratory (if required) for future research, eg., immunology assays, further coagulation assays, or clarification of clinical or laboratory AE, etc. This is optional and participants will sign an additional consent for this research.",
        "footnoteId": "fn_26",
        "sourceText": "z. Samples will be collected prior to any BIVV001 dosing and will be archived by the central laborat"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of response to bleeding episodes using a 4-point bleeding response scale. The participant should record response approximately 72 hours from the time the first BIVV001 injection was administered to treat the bleeding episode, unless treatment of the bleed was administered in the clinic. In that case, the investigator will report the participant's response to treatment via the eCRF.",
        "footnoteId": "fn_27",
        "sourceText": "aa. Participants will record all bleeding episodes in the ePD beginning at Baseline. Assessment of r"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "timing_after",
        "text": "bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated PK sampling after the first dose of BIVV001 (Baseline). See abbreviated PK sampling details in Table 2.",
        "footnoteId": "fn_28",
        "sourceText": "bb. All participants (except those in the sequential PK subgroup of Arm A) will undergo abbreviated "
      },
      {
        "id": "fn_cond_29",
        "conditionType": "timing_at",
        "text": "cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Baseline and again at Week 26. See sequential PK sampling details as described in Table 3.",
        "footnoteId": "fn_29",
        "sourceText": "cc. Participants in the sequential PK subgroup (n=16) will undergo more extensive PK sampling at Bas"
      },
      {
        "id": "fn_cond_30",
        "conditionType": "timing_before",
        "text": "dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 min ± 3 min post injection. This trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ADA) samples taken predose (Table 2).",
        "footnoteId": "fn_30",
        "structuredCondition": "timing.before(rfviiifc-vwf-xten dosing and 15 min ± 3 min post injection. this trough sample should be collected at the same time point as the trough inhibitor and anti-drug antibody (ada) samples taken predose (table 2)., PT30M)",
        "appliesToActivityIds": [
          "PK Peak Sample",
          "PK Trough Sample"
        ],
        "timingConstraint": "PT30M",
        "sourceText": "dd. Peak and trough sample only (collected within 30 min prior to rFVIIIFc-VWF-XTEN dosing and 15 mi"
      },
      {
        "id": "fn_cond_31",
        "conditionType": "general",
        "text": "ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference ≥18 years old or PROMIS Pediatric-SF Pain Interference <18 years old), and Physical Function (PROMIS-SF Physical Function ≥18 years old or PROMIS Pediatric-SF Physical Activity <18 years old). See Section 8.1.2.",
        "footnoteId": "fn_31",
        "sourceText": "ee. PROMIS Assessments to include Pain Intensity, Pain Interference (PROMIS-SF Pain Interference ≥18"
      },
      {
        "id": "fn_cond_32",
        "conditionType": "general",
        "text": "ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patient perception of activity and a single question on patient perception of joint health. See Section 8.1.2.",
        "footnoteId": "fn_32",
        "sourceText": "ff. Patient Global Impression of Severity (PGIS) assessment will include a single question on patien"
      },
      {
        "id": "fn_cond_33",
        "conditionType": "general",
        "text": "gg. Treatment preference survey will consist of 2 questions on patient preference and a single question on Patient Global Impression of Change (PGIC). See Section 8.1.2.",
        "footnoteId": "fn_33",
        "sourceText": "gg. Treatment preference survey will consist of 2 questions on patient preference and a single quest"
      },
      {
        "id": "fn_cond_34",
        "conditionType": "timing_before",
        "text": "hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical grade accelerometer (ActiGraph Activity Monitor) worn on the nondominant wrist. Device will be worn daily for 8 consecutive days after the scheduled visits at Screening, Baseline, Weeks 4, 13, 26, 39, and for 8 consecutive days before the Week 52 visit. Refer to Section 8.1.4",
        "footnoteId": "fn_34",
        "structuredCondition": "duration(P8D)",
        "appliesToActivityIds": [
          "Physical Activity Assessment"
        ],
        "sourceText": "hh. Where available, assessments of physical activity (PA) will be done by using a triaxial medical "
      },
      {
        "id": "fn_cond_35",
        "conditionType": "general",
        "text": "ii. Coagulation parameters include activated partial thromboplastin time (aPTT)",
        "footnoteId": "fn_35",
        "sourceText": "ii. Coagulation parameters include activated partial thromboplastin time (aPTT)"
      },
      {
        "id": "fn_cond_36",
        "conditionType": "general",
        "text": "jj. Please refer to Section 10.11.2 for Italy specific requirement",
        "footnoteId": "fn_36",
        "sourceText": "jj. Please refer to Section 10.11.2 for Italy specific requirement"
      },
      {
        "id": "fn_cond_37",
        "conditionType": "timing_before",
        "text": "kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after the Week 52/EOS Visit, but before the EOS is declared.",
        "footnoteId": "fn_37",
        "sourceText": "kk. Interviews will be conducted with a subset of participants and may be done up to 6 months after "
      },
      {
        "id": "fn_cond_38",
        "conditionType": "general",
        "text": "ll. ePD training only. ePD devices are given to the patients at the baseline visit",
        "footnoteId": "fn_38",
        "sourceText": "ll. ePD training only. ePD devices are given to the patients at the baseline visit"
      },
      {
        "id": "fn_cond_39",
        "conditionType": "general",
        "text": "1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies.",
        "footnoteId": "fn_39",
        "sourceText": "1. Acetylsalicylic acid (ASA) or non-NSAID anti-platelet therapies."
      },
      {
        "id": "fn_cond_40",
        "conditionType": "general",
        "text": "2. NSAIDs at doses above the maximum dose specified in local prescribing information.",
        "footnoteId": "fn_40",
        "sourceText": "2. NSAIDs at doses above the maximum dose specified in local prescribing information."
      },
      {
        "id": "fn_cond_41",
        "conditionType": "general",
        "text": "3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatment of hepatitis C virus [HCV] or HIV). The use of systemic steroids for the treatment of acute respiratory illness (eg, asthma), acute allergic episodes, or otherwise life threatening episodes is allowed. Treatment in these circumstances should not exceed a 14 day duration. Local, topical, and/or inhaled steroid use is permitted.",
        "footnoteId": "fn_41",
        "sourceText": "3. Systemic treatment with chemotherapy and/or other immunosuppressive drugs (except for the treatme"
      },
      {
        "id": "fn_cond_42",
        "conditionType": "general",
        "text": "4. Any other FVIII product (with exceptions listed in Section 7.1.1).",
        "footnoteId": "fn_42",
        "sourceText": "4. Any other FVIII product (with exceptions listed in Section 7.1.1)."
      },
      {
        "id": "fn_cond_43",
        "conditionType": "timing_before",
        "text": "6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of patency of intravenous catheters, and short-term thromboembolic prophylaxis during immobilization and/or perioperatively. The Investigator must discuss the use of anticoagulant agents with the medical monitor. As stated in Section 5.3, participants who routinely administer an additional dose of FVIII prior to a sports activity or increased physical activity will not be allowed to do so in this study. However, the day of dosing BIVV001 in Arms A and B (prophylaxis period) could be chosen prior to a weekly recurring physical activity.",
        "footnoteId": "fn_44",
        "sourceText": "6. Anticoagulant agents, excluding the use of heparin for intermittent flushing for maintenance of p"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Key Secondary: Intra-patient comparison of ABR",
        "endpointType": "Secondary",
        "inputs": [
          "ABR_BIVV001_period",
          "ABR_historical_prophylaxis",
          "study_duration_current",
          "study_duration_observational"
        ],
        "timeWindow": {
          "reference": "BIVV001 weekly prophylaxis treatment period",
          "duration": "P6M"
        },
        "algorithm": "ABR_BIVV001_period - ABR_historical_prophylaxis",
        "successCriteria": "Participants in Arm A must have at least 6 months of study duration in both this study and in observational study 242HA201/OBS16221",
        "sourceText": "an intra-patient comparison of ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR... participants in Arm A must have at least 6 months of study duration i"
      },
      {
        "id": "ep_2",
        "name": "Patient Reported Outcome: TSQM-9",
        "endpointType": "Secondary",
        "inputs": [
          "TSQM-9_scores"
        ],
        "timeWindow": {
          "reference": "Baseline and subsequent visits per SoA",
          "duration": null
        },
        "algorithm": "Calculation of 9-item Treatment Satisfaction Questionnaire for Medication scores",
        "successCriteria": "Evaluation of treatment satisfaction",
        "sourceText": "the 9-item version of the Treatment Satisfaction Questionnaire for Medication (TSQM-9) is being used"
      },
      {
        "id": "ep_3",
        "name": "Exploratory: Patient expectations and perception",
        "endpointType": "Exploratory",
        "inputs": [
          "exit_interview_data"
        ],
        "timeWindow": {
          "reference": "Study Exit",
          "duration": null
        },
        "algorithm": "Qualitative/Quantitative analysis of exit interview responses",
        "successCriteria": "Evaluation of participants’ expectations of treatment and perception of treatment impact",
        "sourceText": "An exit interview... related endpoint was added to the exploratory objective for patient reported outcome measures... To evaluate participants’ expectations of treatment and perception of treatment im"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Patient Global Impression of Change",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Patient Global Impression of Severity"
        ],
        "derivationRule": "Assessment of change in condition compared to baseline status",
        "baselineDefinition": "Baseline assessment at Day 1",
        "baselineVisit": "Day 1",
        "analysisWindow": "Week 26 and Week 52 ± 7 days",
        "imputationRule": "Not specified in text",
        "unit": "Scale"
      },
      {
        "id": "dv_2",
        "name": "FVIII Activity Half-life",
        "variableType": "Custom",
        "sourceVariables": [
          "FVIII activity",
          "one-stage aPTT assay"
        ],
        "derivationRule": "Geometric mean of half-life calculated from sequential PK sampling",
        "baselineDefinition": "Predose PK sample on Day 1",
        "baselineVisit": "Day 1",
        "analysisWindow": "Sequential sampling post-dose",
        "imputationRule": "Not specified in text",
        "unit": "Hours"
      },
      {
        "id": "dv_3",
        "name": "Treatment Emergent Adverse Events (TEAE)",
        "variableType": "Categorical",
        "sourceVariables": [
          "Adverse Events"
        ],
        "derivationRule": "Events occurring after the first dose of BIVV001 or Advate",
        "baselineDefinition": "First dose administration",
        "baselineVisit": "Day 1",
        "analysisWindow": "From Day 1 through Safety follow-up",
        "imputationRule": "Not specified in text",
        "unit": "Count/Incidence"
      },
      {
        "id": "dv_4",
        "name": "FVIII Activity Geometric Mean Ratio (GMR)",
        "variableType": "Custom",
        "sourceVariables": [
          "BIVV001 FVIII activity",
          "Advate FVIII activity"
        ],
        "derivationRule": "Ratio of geometric mean half-life (BIVV001 / Advate)",
        "baselineDefinition": "Comparator dose (Advate) results",
        "baselineVisit": "Day 1",
        "analysisWindow": "PK sampling period",
        "imputationRule": "Not specified in text",
        "unit": "Ratio"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Baseline",
        "Treatment",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Baseline": "BASELINE",
        "Treatment": "TREATMENT",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Following BIVV001",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 50.0,
            "unit": "iu"
          }
        ],
        "sourceText": "with QW dosing, mean FVIII activities based on one-stage and chromogenic assays were 46.28% and 30.46% at 72 hours, 22.30% and 14.48% at 120 hours, and 9.83% and 6.74% at 168 hours, respectively. Foll"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "BIVV001 (efanesoctocog alfa)",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "At least 6 months",
        "doseModifications": [
          "Major surgery only allowed after 6 exposure days (EDs)",
          "Negative inhibitor test required within 4 weeks prior to surgery"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "electronic patient diary (ePD) is performed at the Screening visit. ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "Determination The selection of participants to be included in the analysis for the key secondary efficacy endpoint (ie, an intra-patient comparison of"
      },
      {
        "id": "visit_2",
        "visitName": "Visit 001",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "ABR during the BIVV001 weekly prophylaxis treatment period versus the historical prophylaxis ABR) was updated to clarify that participants in Arm A must have at least 6 months of study duration"
      },
      {
        "id": "visit_4",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Treatment",
        "sourceText": "ePD devices are given to the patients at the baseline visit. In Section 8.3.8, the following text was added: (if a bleed occurs during the Screening period, before the baseline visit, it will be"
      },
      {
        "id": "visit_13",
        "visitName": "EOS",
        "targetDay": null,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": false,
        "visitNumber": 5,
        "sourceText": "EOS/ETc ±7 days Unscheduled"
      },
      {
        "id": "visit_21",
        "visitName": "Visit 52",
        "targetDay": null,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "(EOS) Visit 52 weeks (±7 days) post-Baseline, or earlier if EOS has been declared. 4.2 SCIENTIFIC RATIONALE FOR STUDY DESIGN"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Minor Dental Surgery",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 0,
        "isRequired": false,
        "visitNumber": 4,
        "epoch": "Surgical"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Major Surgery",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 5,
        "epoch": "Surgical"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Safety Follow-up",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Exit Interview",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "End of Study"
      },
      {
        "id": "visit_6",
        "visitName": "Week 1",
        "targetDay": 1,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 1,
        "sourceText": "Table 3 - PK sampling schedule of activities first dose (Week 1) and Week 26 for sequential PK subgroup ................................................................................................"
      },
      {
        "id": "visit_14",
        "visitName": "Day 2",
        "targetDay": 2,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "Day 2 Day 4 Day 8d (study drug can be"
      },
      {
        "id": "visit_15",
        "visitName": "Day 4",
        "targetDay": 4,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 13,
        "sourceText": "Day 4 Day 8d (study drug can be taken after assessments on"
      },
      {
        "id": "visit_19",
        "visitName": "Week 2",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "targetWeek": 2,
        "sourceText": "Note: Participants in the sequential PK subgroup will not receive BIVV001 at Week 2 and Week 27 (or 1 week after the repeat PK). a"
      },
      {
        "id": "visit_17",
        "visitName": "Day 11",
        "targetDay": 11,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 15,
        "sourceText": "Day 11 Day 15e 15 m"
      },
      {
        "id": "visit_18",
        "visitName": "Day 15",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 16,
        "sourceText": "Day 15e 15 m (±3 m)"
      },
      {
        "id": "visit_10",
        "visitName": "Week 4",
        "targetDay": 22,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 17,
        "targetWeek": 4,
        "sourceText": "Week 4c ±7 days Week 13c"
      },
      {
        "id": "visit_11",
        "visitName": "Week 13",
        "targetDay": 85,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 18,
        "targetWeek": 13,
        "sourceText": "Week 13c ±7 days Week"
      },
      {
        "id": "visit_7",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 26,
        "epoch": "Treatment",
        "sourceText": "undergo more extensive PK sampling at Baseline and again at Week 26. Participants from any arm who undergo major surgery during the study will be included in the surgery subset. A minimum of 10 major "
      },
      {
        "id": "visit_12",
        "visitName": "Week 39",
        "targetDay": 267,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 39,
        "sourceText": "Week 39c ±7 days Week 52/"
      },
      {
        "id": "visit_8",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "targetWeek": 52,
        "sourceText": "3 endpoints from baseline to Week 52, along with its 95% CI, will be estimated by the MMRM model. Analysis of other secondary efficacy endpoints: All secondary efficacy endpoints will be"
      },
      {
        "id": "visit_5",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 22,
        "sourceText": "Table 1 - Overall schedule of activities from screening to safety follow-up call or visit................................. 17 Table 2 - Abbreviated PK sampling schedule of activities ................."
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "357:535",
      "method": "Simple randomization",
      "centralRandomization": true,
      "sourceText": "Amended clinical Trial Protocol 05 \nEFC16293 - efanesoctocog alfa       \n20-Aug-2021 \nVersion number: 1 \n \nProperty of the Sanofi group - strictly confidential \nPage 27 \nhemophilia A is estimated to b"
    }
  }
}